Search Results

Get private biotech scaling memos—exclusive strategy notes not shared publicly. Book a Strategy Call Get New Memos by Email Built for BioTech operators • 10–100 FTE • Boston & global Q2: How often are new memos published? Yes - via strategy calls and implementation sprints. Start with a Strategy Call . About Timeline Strategy We build the operating system that enables biotech teams to scale without breaking

Timeline Strategy helps biotech startups build scalable strategy through bold, no-fluff workshops and KPIs that matter ✅ A roadmap your team can actually follow This battle-tested biotech strategy framework Only 3 Teams at a Time. 👉 Let’s Build Your Bulletproof Roadmap The strategy guy for biotech founders Useful Articles About Biotech Strategy From Mirror to Market: The Shift Every Biotech Growth Strategy A new therapeutic platform for a rare disease. Strong in vivo results.

Welcome to the BioTech Scaling Vault. You’ve just joined a private list built for biotech leaders who want to scale beyond the science.

. 👉 Science and strategy slowly stop talking to each other in meaningful moments.   It weakens when science and strategy are no longer part of the same decisions. Strategy focuses on survival. Both are acting rationally within unclear boundaries. It is a strategic choice. When science and strategy disconnect, collaboration weakens. Attila runs focused strategy consultations for biotech founders  who are ready to lead with clarity,

Strong biotech licensing isn’t about validation; it’s about the discipline to protect your future degrees It shows up when founders treat biotech licensing like a moment of validation instead of a strategic A Simple Framework: The Three Levers of Licensing Strategy Think of your licensing agreement as three Strategic Takeaway – Clean Biotech Licensing 👉 The hard truth: Investors don’t just invest in science Attila runs focused strategy consultations for biotech founders who are ready to lead with clarity, not

The AI Buzz Is Real But So Is the Strategy Gap 👉 AI is dominating the biotech conversation right now Why Strategy Still Decides Outcomes Even the most sophisticated AI cannot fix a weak strategy.   . 👉 In biotech, strategy is not optional. It is chasing every new trend without a clear sense of purpose, burning resources and momentum with nothing Attila runs focused strategy consultations for biotech founders  who are ready to lead with clarity,